Singapore, June 19 -- Immuno Cure BioTech, a clinical-stage biotechnology startup based in Hong Kong Science Park, has announced its upcoming collaboration with PharmaJet(R) to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, delivered via PharmaJet's innovative Tropis(R) needle-free injection system in a clinical study.

Immuno Cure and PharmaJet held a material transfer agreement (MTA) signing ceremony at the BIO 2025 International Convention inBoston,USAto commemorate such collaboration.

ICVAX employs Immuno Cure's patented PD-1-Enhanced DNA Vaccine technology, which aims to achieve sustained, immune-mediated HIV-1 virological control without the need ofAntiretroviral therapy (ART).

Following the successf...